| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 74521 |
Fmoc-PEG3-Val-Cit，N-Fluorenylmethoxycarbonyl-triethylene glycol-Val-Cit |
81 |
WYQ |
2024-12-19 |
| 74522 |
CAS: 2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP |
78 |
WYQ |
2024-12-19 |
| 74523 |
CAS: 2055024-64-9，Azido-PEG4-Val-Cit-PAB-OH |
81 |
WYQ |
2024-12-19 |
| 74524 |
CAS: 870487-09-5，Boc-Val-Cit-PAB |
84 |
WYQ |
2024-12-19 |
| 74525 |
CAS:784105-33-5 Amino-PEG3-C2-acid的介绍 |
72 |
zyl |
2024-12-19 |
| 74526 |
CAS 863971-53-3：Fmoc-Val-Cit-PAB-PNP |
87 |
WYQ |
2024-12-19 |
| 74527 |
Ald-Ph-amido-PEG11-C2-NH2 CAS:1337889-01-6 |
69 |
zyl |
2024-12-19 |
| 74528 |
cas:2003260-13-5 ， MA-PEG4-Ala-Ala-PAB-PNP，ADC定制 |
72 |
wyh |
2024-12-19 |
| 74529 |
DOTA-NCS-6-Ahx-Phe 19-ST[1-19] DOTA偶联ST肽类似物 |
102 |
h |
2024-12-19 |
| 74530 |
1,4,7,10-四氮杂-n-(1-羧基-3-(4-硝基苯基)丙基)-n,N , N ‴-tris(acetic酸)环十二烷(PA-DOTA) |
67 |
h |
2024-12-19 |
| 74531 |
CAS 159858-22-7：Fmoc-Val-Cit-PAB-OH |
61 |
WYQ |
2024-12-19 |
| 74532 |
cas:5117-19-1，Octanethyl glycol ，八乙二醇的主要特点 |
97 |
zyl |
2024-12-19 |
| 74533 |
CAS 159857-79-1：Val-Cit-PAB-OH，缬氨酸（Val）、琥珀酰亚胺（Cit）和对氨基苯甲酸（PAB）的衍生物 |
106 |
WYQ |
2024-12-19 |
| 74534 |
SPDP-Val-Cit-PAB-OH，ADC定制 |
67 |
wyh |
2024-12-19 |
| 74535 |
DOTA-LVT 螯合剂DOTA偶联Lys8-血管收缩素 |
97 |
h |
2024-12-19 |
| 74536 |
cas:2054345-67-2，azido-tris(ethylenoxy)-L-alanine TFA Salt化学性质 |
83 |
zyl |
2024-12-19 |
| 74537 |
cas:68617-64-1，SPDP acid，3-(2-吡啶二硫代)丙酸的合成方法 |
119 |
zyl |
2024-12-19 |
| 74538 |
1,4,7,10-四(羧甲基)-1,4,7,10-四氮杂环十二烷单酰胺偶联葡萄糖 |
84 |
h |
2024-12-19 |
| 74539 |
PEG-P(Asp-Gd-DOTA)Gd‐DOTA偶联聚乙二醇改性聚天冬氨酸 |
89 |
h |
2024-12-19 |
| 74540 |
cas:70539-42-3，EGS Crosslinker，乙二醇-双(琥珀酸N-羟基琥珀酰亚胺酯)的结构式 |
140 |
zyl |
2024-12-19 |
| 74541 |
CXCR4导向的五肽[(68)Ga]喷替沙福(环(-D-Tyr-N-Me-D-Orn(AMB-DOTA)-L-Arg-L-2-Nal-Gly-)) |
118 |
h |
2024-12-19 |
| 74542 |
α-hexadecyl-DOTA α-十六烷基-DOTA |
83 |
h |
2024-12-19 |
| 74543 |
Methyltetrazine-SS-NHS 甲基四唑-双硫键-活性酯的合成方法 |
75 |
zyl |
2024-12-19 |
| 74544 |
DOTA-AgRP-6E |
110 |
h |
2024-12-19 |
| 74545 |
DOTA-morab-003 DOTA偶联单克隆抗体MORAb-003 |
73 |
h |
2024-12-19 |
| 74546 |
DOTA-Bz-folate DOTA-Bz-叶酸 |
91 |
h |
2024-12-19 |
| 74547 |
cas:55750-53-3，6-Maleimidocaproic acid，6-马来酰亚氨基己酸 |
102 |
zyl |
2024-12-19 |
| 74548 |
cas: Fmoc-PEG3-Val-Cit，ADC定制 |
80 |
wyh |
2024-12-19 |
| 74549 |
钆(III)DOTA-DSPE脂质体 |
78 |
h |
2024-12-19 |
| 74550 |
CAS: 870487-08-4，Boc-Val-Cit，叔丁氧羰基-缬氨酰-L-瓜氨酸 |
70 |
WYQ |
2024-12-19 |
| 74551 |
DOTA-Phe-D-Trp-Lys-Thr-OMe DOTA偶联生长抑素四肽类似物 |
102 |
h |
2024-12-19 |
| 74552 |
CAS: 35665-38-4，Fmoc-Gly-Gly-OH，Fmoc-甘氨酰-甘氨酸 |
104 |
WYQ |
2024-12-19 |
| 74553 |
cas:117235-10-6，3-Mercaptopropanyl-N-hydroxysuccinimide ester的结构式 |
102 |
zyl |
2024-12-19 |
| 74554 |
DOTA-PEG(4)-BBN(7-14)-AuNP DOTA-神经介素n功能化NHS活化的PEG-金纳米颗粒 |
72 |
h |
2024-12-19 |
| 74555 |
cas:2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP，ADC定制 |
64 |
wyh |
2024-12-19 |
| 74556 |
CAS: 863971-53-3，Fmoc-Val-Cit-PAB-PNP |
84 |
WYQ |
2024-12-19 |
| 74557 |
tris-苄基-DOTA tris-benzyl-DOTA |
103 |
h |
2024-12-19 |
| 74558 |
DOTA-DN(PTX)-BN DOTA-铃蟾肽功能化聚酰胺胺(PAMAM)树状大分子(DN)负载紫杉醇 |
90 |
h |
2024-12-19 |
| 74559 |
NH2-Sar10-COOH，ADC定制 |
73 |
wyh |
2024-12-19 |
| 74560 |
cas:1415328-95-8，NHPI-PEG4-C2-NHS ester |
91 |
zyl |
2024-12-19 |
| 74561 |
Gd-GlyMe-DOTA-全氟辛基甘露糖缀合物(Gadofluorine M) |
127 |
h |
2024-12-19 |
| 74562 |
MC-Val-Cit-PAB-PNP（CAS号：159857-81-5） |
113 |
WYQ |
2024-12-19 |
| 74563 |
Mal-Gly-Gly-L-Phe-N-[(carboxymethoxy)methyl]Glycinamide，ADC定制 |
83 |
wyh |
2024-12-19 |
| 74564 |
L-RNA寡核苷酸的功能化DOTA |
91 |
h |
2024-12-19 |
| 74565 |
MA-PEG4-Glu(t-Bu)-Val-Cit-PAB-PNP，在药物递送系统中具有广泛应用潜力 |
77 |
WYQ |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询